Medtronic Announces Price of $2 Billion Senior Notes

AI Basics

Dublin, March 23, 2023 /PRNewswire/ — Medtronic plc (the “Company”) (NYSE: MDT) today announced that its wholly-owned subsidiary, Medtronic Global Holdings SCA (“Medtronic Luxco”), $1,000,000,000 Principal of 4.25% Senior Notes due 2028 and $1,000,000,000 Principal Amount 4.50% Senior Notes due 2033 (collectively, the “Notes”). All obligations of Medtronic Luxco under the Notes are fully and unconditionally guaranteed on a senior unsecured basis by the Company and Medtronic, Inc., a wholly owned indirect subsidiary of Medtronic Luxco.

The net proceeds from the offering are Medtronic Luxco, the Company, Medtronic, Inc. Mizuho Bank, Ltd. as an administrative agent, as a lender and for general corporate purposes.Offering is expected to end on March 30, 2023, subject to customary closing conditions. The joint managing companies for the offering are Barclays Capital, JP Morgan Securities and Mizuho Securities. united states of america LLC.

Offering made solely by dated prospectus March 3, 2023 and the Prospectus Supplement (collectively, the “Prospectus”). These documents are available free of charge by visiting EDGAR on the Securities and Exchange Commission’s website at Alternatively, a copy of the offering prospectus may be obtained by contacting Barclays Capital Inc. toll-free at 1-888-603-5847, JP Morgan Securities LLC, c/o Broadridge Financial Solutions, Attn. can. : Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, Phone: 1-866-803-9204, Mizuho Securities united states of america LLC, Toll Free 1-866-271-7403.

About Medtronic
bold thinking. bolder action. We are Medtronic. Headquartered in Medtronic plc Dublin, Irelandis the world’s leading healthcare technology company, boldly tackling and finding solutions to some of the toughest health challenges facing humanity. Our mission to relieve pain, restore health and extend life brings together his global team of over 90,000 passionate people across 150 countries. Our technology and therapies treat 70 health conditions and include cardiac machines, surgical robots, insulin pumps, surgical instruments, patient monitoring systems and more. Fueled by our diverse knowledge, our insatiable curiosity, and our desire to help all who need it, we strive every second, every hour, every day to create life-changing innovations for two people. We provide technology. Expect more from us for insightful care, people-first experiences, and better results for the world. In everything we do, we design something extraordinary.

Forward-Looking Statements

This press release contains forward-looking statements regarding future events that are subject to safe harbors created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1934 and the Securities Exchange Act. may be deemed to contain references to statements that may be viewed as forward-looking statements rather than statements of historical fact, including statements regarding the offering and the anticipated use of proceeds therefrom, and the expected closing date of the offering. Including but not limited to:

Particular attention should be paid to the important risk factors and cautions referenced in the “Risk Factors” section of the prospectus relating to the offering and those contained in Medtronic plc’s filings with the SEC. there is. Factors included in Medtronic plc’s most recent annual report on Form 10-K. Medtronic plc does not undertake to update any forward-looking statements.

contact address:

Erica Winkels

Ryan Weisfenning

public relations

PR for investors



Source Medtronic plc

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *